Cargando…

Simultaneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells

Despite the demonstrated benefits of anti-EGFR/VEGF targeted therapies in metastatic colorectal cancer (mCRC), many patients initially respond, but then show evidence of disease progression. New therapeutic strategies are needed to make the action of available drugs more efficient. Our study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valverde, Araceli, Peñarando, Jon, Cañas, Amanda, López-Sánchez, Laura M., Conde, Francisco, Hernández, Vanessa, Peralbo, Esther, López-Pedrera, Chary, de la Haba-Rodríguez, Juan, Aranda, Enrique, Rodríguez-Ariza, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479446/ https://www.ncbi.nlm.nih.gov/pubmed/26107817 http://dx.doi.org/10.1371/journal.pone.0131363

Ejemplares similares

CoCl(2), a Mimic of Hypoxia, Induces Formation of Polyploid Giant Cells with Stem Characteristics in Colon Cancer
por: Lopez-Sánchez, Laura M., et al.
Publicado: (2014)

The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β-catenin signaling axis
por: Valverde, Araceli, et al.
Publicado: (2017)

Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors
por: Cañas, Amanda, et al.
Publicado: (2012)

SWATH‐based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours
por: López‐Sánchez, Laura M., et al.
Publicado: (2019)

A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer
por: Peñarando, Jon, et al.
Publicado: (2018)

Clinical Utility of microRNAs in Exhaled Breath Condensate as Biomarkers for Lung Cancer
por: Pérez-Sánchez, Carlos, et al.
Publicado: (2021)

Cardiovascular Risk in Systemic Autoimmune Diseases: Epigenetic Mechanisms of Immune Regulatory Functions
por: López-Pedrera, Chary, et al.
Publicado: (2012)

KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
por: Morales-Estevez, Cristina, et al.
Publicado: (2016)

Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
por: Yuan, Xiao-Han, et al.
Publicado: (2018)

Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer
por: Shi, Xiaoyan, et al.
Publicado: (2008)

Editorial: Clinical management, pathogenesis and biomarkers of cardiovascular disease associated with systemic autoimmune disorders
por: Perez-Sanchez, Carlos, et al.
Publicado: (2022)

Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma
por: Longatto-Filho, Adhemar, et al.
Publicado: (2009)

Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Role of Proinflammatory Cytokines and Therapeutic Approaches
por: López-Pedrera, Chary, et al.
Publicado: (2010)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

The 5-lipoxygenase/cyclooxygenase-2 cross-over metabolite, hemiketal E(2), enhances VEGFR2 activation and promotes angiogenesis
por: Nakashima, Fumie, et al.
Publicado: (2023)

Influence of variability in the cyclooxygenase pathway on cardiovascular outcomes of nephrosclerosis patients
por: González, Luz M., et al.
Publicado: (2023)

Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors
por: Saleh, Nashwa M., et al.
Publicado: (2020)

Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis
por: Zhang, Xinji, et al.
Publicado: (2012)

The cyclooxygenases
por: Chandrasekharan, NV, et al.
Publicado: (2004)

Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma
por: Onda, Maho, et al.
Publicado: (2023)

Metal-free domino amination-Knoevenagel condensation approach to access new coumarins as potent nanomolar inhibitors of VEGFR-2 and EGFR
por: Eliwa, Essam M., et al.
Publicado: (2021)

Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab
por: Ortiz-Morales, M. José, et al.
Publicado: (2022)

Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors
por: Sun, Shaofeng, et al.
Publicado: (2017)

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
por: Kaufman, Nichole E. M., et al.
Publicado: (2021)

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches
por: Lopez-Pedrera, Chary, et al.
Publicado: (2019)

Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer
por: Toledano-Fonseca, Marta, et al.
Publicado: (2020)

The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy
por: Mabeta, Peace, et al.
Publicado: (2022)

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2009)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk
por: Barbarroja, Nuria, et al.
Publicado: (2022)

Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts
por: Guil-Luna, Silvia, et al.
Publicado: (2020)

Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-α therapy effectiveness
por: Ruiz-Limon, Patricia, et al.
Publicado: (2020)

MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma
por: Kinget, Lisa, et al.
Publicado: (2021)

The Combination of Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer
por: Toledano-Fonseca, Marta, et al.
Publicado: (2021)

Inhibition of lung tumor growth by targeting EGFR/VEGFR-Akt/NF-κB pathways with novel theanine derivatives
por: Zhang, Guoying, et al.
Publicado: (2014)

Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
por: Zhao, Tong T., et al.
Publicado: (2010)

The Cat Mandible (II): Manipulation of the Jaw, with a New Prosthesis Proposal, to Avoid Iatrogenic Complications
por: Lombardero, Matilde, et al.
Publicado: (2021)

Cyclooxygenase and Prostaglandin in Cancer
por: Kim, Jong-Woo
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pqrkgo7ecgibttmncrkrlnh76q